Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Published 1 June 2009, doi:10.1136/bmj.b1728
Cite this as: BMJ 2009;338:b1728
Henry Krum
1 Centre of Cardiovascular Research & Education in Therapeutics, Dept of Epidemiology & Preventive Medicine, School of Public Health & Preventive Medicine, Monash University, Melbourne 3004, Australia
Correspondence to: H Krum henry.krum@med.monash.edu.au
β blockers remain underused in chronic heart failure despite important benefits, but the difficulty in starting treatment is probably overestimated
| The first 150 words of the full text of this article appear below. |
|
Chronic systolic heart failure is a major public health problem that is associated with high mortality, poor quality of life, and frequent hospitalisation.1 The sympathetic nervous system is a key activated neurohormonal system that drives progression of this disorder; blocking this system with β adrenergic blocking drugs can improve clinical outcomes.2 However, the underuse of β blockers is well documented,3 4 whether by cardiologists or by other specialists,
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?
Read all Rapid Responses